United Therapeutics Corporation (UTHR)
USD 278.91
(-4.63%)
USD 278.91
(-4.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.18 Billion USD | 20.95% |
| 2022 | 979.7 Million USD | 76.24% |
| 2021 | 555.9 Million USD | -6.35% |
| 2020 | 593.6 Million USD | 416.42% |
| 2019 | -187.6 Million USD | -123.29% |
| 2018 | 805.4 Million USD | -1.17% |
| 2017 | 814.9 Million USD | -23.25% |
| 2016 | 1.06 Billion USD | 51.89% |
| 2015 | 699.01 Million USD | 29.74% |
| 2014 | 538.8 Million USD | 84.21% |
| 2013 | 292.49 Million USD | -30.63% |
| 2012 | 421.64 Million USD | 32.68% |
| 2011 | 317.78 Million USD | 93.76% |
| 2010 | 164 Million USD | 530.76% |
| 2009 | 26 Million USD | 131.69% |
| 2008 | -82.05 Million USD | -1401.86% |
| 2007 | 6.3 Million USD | -78.25% |
| 2006 | 28.98 Million USD | -32.43% |
| 2005 | 42.89 Million USD | 224.73% |
| 2004 | 13.2 Million USD | 214.6% |
| 2003 | -11.52 Million USD | 35.98% |
| 2002 | -18 Million USD | 61.65% |
| 2001 | -46.93 Million USD | 42.41% |
| 2000 | -81.5 Million USD | -130.23% |
| 1999 | -35.4 Million USD | -166.17% |
| 1998 | -13.3 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 343.1 Million USD | 7.25% |
| 2024 Q2 | 319.9 Million USD | -10.22% |
| 2024 Q1 | 356.3 Million USD | 36.99% |
| 2023 Q2 | 313.4 Million USD | 10.2% |
| 2023 Q3 | 327 Million USD | 4.34% |
| 2023 Q4 | 260.1 Million USD | -20.46% |
| 2023 FY | 1.18 Billion USD | 20.95% |
| 2023 Q1 | 284.4 Million USD | 61.96% |
| 2022 Q1 | 288 Million USD | 69.61% |
| 2022 FY | 979.7 Million USD | 76.24% |
| 2022 Q4 | 175.6 Million USD | -44.13% |
| 2022 Q3 | 314.3 Million USD | 100.45% |
| 2022 Q2 | 156.8 Million USD | -45.56% |
| 2021 Q4 | 169.8 Million USD | -25.75% |
| 2021 Q2 | 222.2 Million USD | 442.9% |
| 2021 FY | 555.9 Million USD | -6.35% |
| 2021 Q3 | 228.7 Million USD | 2.93% |
| 2021 Q1 | -64.8 Million USD | -199.23% |
| 2020 Q2 | 140.5 Million USD | -15.72% |
| 2020 Q4 | 65.3 Million USD | -70.47% |
| 2020 Q3 | 221.1 Million USD | 57.37% |
| 2020 FY | 593.6 Million USD | 416.42% |
| 2020 Q1 | 166.7 Million USD | 162.52% |
| 2019 Q1 | -655.9 Million USD | -598.78% |
| 2019 FY | -187.6 Million USD | -123.29% |
| 2019 Q2 | 221.4 Million USD | 133.76% |
| 2019 Q3 | 183.4 Million USD | -17.16% |
| 2019 Q4 | 63.5 Million USD | -65.38% |
| 2018 Q3 | 149.6 Million USD | -31.19% |
| 2018 FY | 805.4 Million USD | -1.17% |
| 2018 Q1 | 306.9 Million USD | 120.79% |
| 2018 Q2 | 217.4 Million USD | -29.16% |
| 2018 Q4 | 131.5 Million USD | -12.1% |
| 2017 Q2 | 88.5 Million USD | -66.43% |
| 2017 Q4 | 139 Million USD | -57.07% |
| 2017 FY | 814.9 Million USD | -23.25% |
| 2017 Q1 | 263.6 Million USD | 51.32% |
| 2017 Q3 | 323.8 Million USD | 265.88% |
| 2016 Q4 | 174.2 Million USD | -26.99% |
| 2016 Q2 | 285.2 Million USD | -21.58% |
| 2016 Q1 | 363.7 Million USD | 134.56% |
| 2016 FY | 1.06 Billion USD | 51.89% |
| 2016 Q3 | 238.6 Million USD | -16.34% |
| 2015 Q3 | 387.07 Million USD | 125.43% |
| 2015 FY | 699.01 Million USD | 29.74% |
| 2015 Q4 | 155.05 Million USD | -59.94% |
| 2015 Q2 | 171.7 Million USD | 1258.13% |
| 2015 Q1 | -14.82 Million USD | -108.3% |
| 2014 Q1 | 216.14 Million USD | 858.63% |
| 2014 Q3 | -32.23 Million USD | -118.28% |
| 2014 Q4 | 178.57 Million USD | 653.96% |
| 2014 Q2 | 176.32 Million USD | -18.42% |
| 2014 FY | 538.8 Million USD | 84.21% |
| 2013 Q1 | 94.03 Million USD | -26.88% |
| 2013 FY | 292.49 Million USD | -30.63% |
| 2013 Q4 | -28.49 Million USD | -127.23% |
| 2013 Q3 | 104.64 Million USD | -14.44% |
| 2013 Q2 | 122.3 Million USD | 30.06% |
| 2012 FY | 421.64 Million USD | 32.68% |
| 2012 Q3 | 80.71 Million USD | -23.55% |
| 2012 Q1 | 106.73 Million USD | 68.07% |
| 2012 Q4 | 128.6 Million USD | 59.32% |
| 2012 Q2 | 105.58 Million USD | -1.08% |
| 2011 Q4 | 63.5 Million USD | -38.33% |
| 2011 Q2 | 135.65 Million USD | 267.8% |
| 2011 Q3 | 102.97 Million USD | -24.09% |
| 2011 FY | 317.78 Million USD | 93.76% |
| 2011 Q1 | 36.88 Million USD | 307.5% |
| 2010 Q2 | 60.82 Million USD | 88.63% |
| 2010 Q1 | 32.24 Million USD | 1577.82% |
| 2010 Q3 | 61.88 Million USD | 1.73% |
| 2010 Q4 | 9.05 Million USD | -85.37% |
| 2010 FY | 164 Million USD | 530.76% |
| 2009 FY | 26 Million USD | 131.69% |
| 2009 Q4 | -2.18 Million USD | -118.59% |
| 2009 Q3 | 11.73 Million USD | 384.81% |
| 2009 Q2 | -4.12 Million USD | -120.04% |
| 2009 Q1 | 20.56 Million USD | 115.36% |
| 2008 Q2 | 18.99 Million USD | 28.71% |
| 2008 Q3 | 18.06 Million USD | -4.9% |
| 2008 Q4 | -133.86 Million USD | -841.2% |
| 2008 FY | -82.05 Million USD | -1401.86% |
| 2008 Q1 | 14.75 Million USD | 275.75% |
| 2007 Q2 | 8.04 Million USD | 207.2% |
| 2007 Q4 | -8.39 Million USD | -159.3% |
| 2007 Q3 | 14.15 Million USD | 75.97% |
| 2007 Q1 | -7.5 Million USD | -311.47% |
| 2007 FY | 6.3 Million USD | -78.25% |
| 2006 Q3 | 11.43 Million USD | -0.72% |
| 2006 Q4 | 3.54 Million USD | -68.96% |
| 2006 FY | 28.98 Million USD | -32.43% |
| 2006 Q1 | 2.48 Million USD | -76.01% |
| 2006 Q2 | 11.51 Million USD | 363.61% |
| 2005 Q3 | 14.53 Million USD | 30.21% |
| 2005 FY | 42.89 Million USD | 224.73% |
| 2005 Q1 | 6.83 Million USD | 8.31% |
| 2005 Q2 | 11.16 Million USD | 63.23% |
| 2005 Q4 | 10.35 Million USD | -28.76% |
| 2004 FY | 13.2 Million USD | 214.6% |
| 2004 Q4 | 6.31 Million USD | 10.81% |
| 2004 Q3 | 5.69 Million USD | 59.56% |
| 2004 Q2 | 3.57 Million USD | 250.48% |
| 2004 Q1 | -2.37 Million USD | 32.64% |
| 2003 FY | -11.52 Million USD | 35.98% |
| 2003 Q4 | -3.52 Million USD | -102.12% |
| 2003 Q3 | -1.74 Million USD | 38.37% |
| 2003 Q2 | -2.82 Million USD | 17.6% |
| 2003 Q1 | -3.43 Million USD | -10.25% |
| 2002 Q2 | -1.37 Million USD | 80.23% |
| 2002 FY | -18 Million USD | 61.65% |
| 2002 Q4 | -3.11 Million USD | 52.38% |
| 2002 Q3 | -6.53 Million USD | -374.04% |
| 2002 Q1 | -6.97 Million USD | 26.67% |
| 2001 Q3 | -11.89 Million USD | 8.29% |
| 2001 Q2 | -12.97 Million USD | -3.32% |
| 2001 FY | -46.93 Million USD | 42.41% |
| 2001 Q1 | -12.55 Million USD | 59.59% |
| 2001 Q4 | -9.51 Million USD | 20.05% |
| 2000 Q3 | -10.42 Million USD | 65.85% |
| 2000 Q4 | -31.06 Million USD | -198.09% |
| 2000 FY | -81.5 Million USD | -130.23% |
| 2000 Q1 | -9.48 Million USD | 0.12% |
| 2000 Q2 | -30.51 Million USD | -221.64% |
| 1999 Q2 | -6.2 Million USD | 49.59% |
| 1999 FY | -35.4 Million USD | -166.17% |
| 1999 Q4 | -9.5 Million USD | -33.8% |
| 1999 Q1 | -12.3 Million USD | 0.0% |
| 1999 Q3 | -7.1 Million USD | -14.52% |
| 1998 FY | -13.3 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 599.522% |
| Alkermes plc | 414.12 Million USD | -186.123% |
| Agenus Inc. | -159.54 Million USD | 842.656% |
| Aptorum Group Limited | -10.52 Million USD | 11359.744% |
| Ardelyx, Inc. | -63.27 Million USD | 1972.59% |
| Dyadic International, Inc. | -8.22 Million USD | 14497.783% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 99504.362% |
| Lantern Pharma Inc. | -17.87 Million USD | 6727.858% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 5998.02% |
| Novavax, Inc. | -566.51 Million USD | 309.157% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 1723.618% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 1541.554% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 6201.908% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 11317.457% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 2330.342% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 411.409% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 4974.806% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 3228.945% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 1018.613% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 1512.041% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 6855.801% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 2792.343% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 4869.361% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 952.256% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 519.917% |
| AlloVir, Inc. | -181.33 Million USD | 753.446% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 677.994% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 4149.833% |
| Bicycle Therapeutics plc | -189.94 Million USD | 723.809% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 789.77% |
| ChromaDex Corporation | -5.59 Million USD | 21262.708% |
| Chimerix, Inc. | -93.06 Million USD | 1373.196% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 2728.596% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 1120.946% |
| CRISPR Therapeutics AG | -222.53 Million USD | 632.448% |
| Precision BioSciences, Inc. | -43.73 Million USD | 2809.21% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 721.959% |
| Fortress Biotech, Inc. | -142.34 Million USD | 932.432% |
| Fortress Biotech, Inc. | -142.34 Million USD | 932.432% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 1312.869% |
| ImmuCell Corporation | -5.74 Million USD | 20713.847% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 981.432% |
| Immix Biopharma, Inc. | -16.14 Million USD | 7440.882% |
| Incyte Corporation | 620.52 Million USD | -90.951% |
| Innoviva, Inc. | 176.7 Million USD | -570.537% |
| IO Biotech, Inc. | -91.44 Million USD | 1395.78% |
| Jaguar Health, Inc. | -34.29 Million USD | 3555.426% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 797.242% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -9822.124% |
| ContextLogic Inc. | -328 Million USD | 461.25% |
| MiMedx Group, Inc. | 37.11 Million USD | -3092.424% |
| MEI Pharma, Inc. | 14.54 Million USD | -8048.123% |
| NextCure, Inc. | -67.63 Million USD | 1851.852% |
| Onconetix, Inc. | -36.03 Million USD | 3388.229% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 2940.533% |
| Opthea Limited | -191.84 Million USD | 717.641% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 43158.697% |
| Vaxcyte, Inc. | -468.04 Million USD | 353.162% |
| PDS Biotechnology Corporation | -43.04 Million USD | 2852.686% |
| Precigen, Inc. | -88.92 Million USD | 1432.501% |
| Pharming Group N.V. | -4.87 Million USD | 24383.007% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 808.198% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 4082.054% |
| PureTech Health plc | -146.19 Million USD | 910.471% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 5882.539% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 602.933% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 4974.806% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 532.437% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 4143.337% |
| Acelyrin, Inc. | -422.06 Million USD | 380.739% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 9188975.636% |
| Summit Therapeutics Inc. | -89.73 Million USD | 1420.429% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 3296.903% |
| Senti Biosciences, Inc. | -92.72 Million USD | 1377.837% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 1132.386% |
| Elevation Oncology, Inc. | -45.44 Million USD | 2707.328% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 3557.846% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 30157.98% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 37573.118% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 3688.323% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 14038.36% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 1842.603% |
| Seer, Inc. | -103.46 Million USD | 1245.24% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 1901.883% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 1747.227% |
| ESSA Pharma Inc. | -32.13 Million USD | 3787.36% |
| GlycoMimetics, Inc. | -39.27 Million USD | 3116.909% |
| GT Biopharma, Inc. | -13.57 Million USD | 8827.902% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 640.505% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 2661.614% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -1264.903% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 2187.598% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 2400.509% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 12023.348% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 334.952% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 17277.443% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 2437.404% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 556.329% |
| Aptose Biosciences Inc. | -52.35 Million USD | 2363.16% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 8316.619% |
| Soligenix, Inc. | -7.69 Million USD | 15492.43% |
| Century Therapeutics, Inc. | -146.54 Million USD | 908.552% |
| Kura Oncology, Inc. | -165.8 Million USD | 814.639% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 1367.842% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 14343.298% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 47846.671% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 18374.213% |
| Autolus Therapeutics plc | -195.02 Million USD | 707.554% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 1499.648% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 1708.563% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 5706.34% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 621.902% |
| GRI Bio, Inc. | -11.38 Million USD | 10505.726% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 26339.477% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 1003.173% |
| IGM Biosciences, Inc. | -263.46 Million USD | 549.744% |
| INmune Bio, Inc. | -29.74 Million USD | 4084.062% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 1171.193% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 3211.99% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 7515.19% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 7613.239% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 2039.343% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 1202.007% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 529.302% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 683.123% |
| Verastem, Inc. | -92.08 Million USD | 1386.76% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 2613.843% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 743.46% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 1100.929% |
| Histogen Inc. | -10.64 Million USD | 11233.139% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 7758.37% |
| Surrozen, Inc. | -45.78 Million USD | 2688.248% |
| Organovo Holdings, Inc. | -15.08 Million USD | 7954.302% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 23377.899% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 2098.77% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 2410.017% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 4787.104% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 15623.705% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 791.779% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 2545.717% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 1615.121% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 7884.755% |
| Apollomics, Inc. | -54.83 Million USD | 2260.886% |
| Amarin Corporation plc | -67.58 Million USD | 1853.122% |
| Mesoblast Limited | -58.79 Million USD | 2115.342% |
| Turnstone Biologics Corp. | -59.03 Million USD | 2107.216% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 815.822% |
| Synaptogenix, Inc. | -8.31 Million USD | 14352.115% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 8223.543% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 1392.275% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 24829.383% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 13517.149% |
| Exelixis, Inc. | 170.88 Million USD | -593.39% |
| Better Therapeutics, Inc. | -38.26 Million USD | 3196.806% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 864.141% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 329.134% |
| NLS Pharmaceutics AG | -11.8 Million USD | 10135.519% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 14834.069% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 4050.588% |
| Gritstone bio, Inc. | -154.63 Million USD | 866.261% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 1820.713% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 7019.911% |
| Avid Bioservices, Inc. | -18.67 Million USD | 6443.827% |
| Insmed Incorporated | -709.62 Million USD | 266.975% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 7652.046% |
| MediWound Ltd. | -15.29 Million USD | 7849.509% |
| OmniAb, Inc. | -69.41 Million USD | 1806.881% |
| Alector, Inc. | -151.74 Million USD | 880.875% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 1197.302% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 2372.187% |
| Zai Lab Limited | -366.57 Million USD | 423.237% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 474.049% |
| Aura Biosciences, Inc. | -84.99 Million USD | 1494.148% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 582.65% |
| Immunic, Inc. | -99.22 Million USD | 1294.179% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 927.687% |
| Veracyte, Inc. | -85.79 Million USD | 1481.083% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 520.453% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 8438.494% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 17302.513% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 6405.136% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | -104.794% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 4755.247% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -2953.709% |
| TG Therapeutics, Inc. | 20.63 Million USD | -5642.742% |
| Galecto, Inc. | -39.9 Million USD | 3069.302% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 2916.229% |
| Fortrea Holdings Inc. | 63.1 Million USD | -1777.813% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 943.675% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 4203.123% |
| XBiotech Inc. | -37.51 Million USD | 3258.891% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 1820.713% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 1865.346% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 1198.085% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 4715.534% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 2323.411% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 308.166% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 1609.581% |
| Vaxxinity, Inc. | -58.28 Million USD | 2132.942% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 1242.524% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 5424.644% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 1471.158% |
| NexImmune, Inc. | -29.19 Million USD | 4158.922% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 21183.135% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 8226.118% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 70.722% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 4754.15% |
| Scopus BioPharma Inc. | -11.71 Million USD | 10214.489% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 1032.537% |
| Ainos, Inc. | -13.2 Million USD | 9072.168% |
| Pluri Inc. | -22.15 Million USD | 5447.504% |
| Prothena Corporation plc | -191.03 Million USD | 720.25% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 958.387% |
| Celularity Inc. | -192.28 Million USD | 716.214% |
| Rallybio Corporation | -78.93 Million USD | 1601.166% |
| Cue Biopharma, Inc. | -52.14 Million USD | 2372.143% |
| MeiraGTx Holdings plc | -137.06 Million USD | 964.506% |
| Omeros Corporation | -164.53 Million USD | 820.173% |
| Humacyte, Inc. | -100.04 Million USD | 1284.343% |
| Immunocore Holdings plc | -59.64 Million USD | 2086.454% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 6484.503% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 4939.685% |
| Blueprint Medicines Corporation | -486.27 Million USD | 343.668% |
| CalciMedica, Inc. | -21.87 Million USD | 5516.686% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 1687.061% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 1001.167% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 791.731% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 462.466% |
| Pulmatrix, Inc. | -14.74 Million USD | 8138.67% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 3414.869% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 1433.356% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 329.948% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 1854.082% |
| Cytokinetics, Incorporated | -496.2 Million USD | 338.792% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 3542.575% |
| Nutriband Inc. | -4.87 Million USD | 24420.977% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 2816.85% |
| Vor Biopharma Inc. | -126.03 Million USD | 1040.128% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 72.068% |
| Evogene Ltd. | -26.39 Million USD | 4589.788% |
| ProKidney Corp. | -151.52 Million USD | 881.999% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 1936.058% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 15503.832% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 295.087% |
| CorMedix Inc. | -48.95 Million USD | 2520.248% |
| BioLineRx Ltd. | -49.69 Million USD | 2484.392% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 1137.811% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 3212.261% |
| Atai Life Sciences N.V. | -125.47 Million USD | 1044.362% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 1551.384% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 1555.49% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 575.886% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 3954.587% |
| MediciNova, Inc. | -9.9 Million USD | 12068.367% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 1037.621% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 16460.465% |
| GeoVax Labs, Inc. | -26.74 Million USD | 4530.702% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 611.118% |
| Biomea Fusion, Inc. | -126.13 Million USD | 1039.39% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 439.122% |
| Mereo BioPharma Group plc | -28.41 Million USD | 4269.834% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 720.078% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 615.277% |
| Absci Corporation | -115.51 Million USD | 1125.754% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 4395.139% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 1149.82% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 589.301% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 4802.731% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 669.68% |
| Allakos Inc. | -196.05 Million USD | 704.368% |
| Imunon, Inc. | -21.03 Million USD | 5734.217% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 1170.719% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -1004.472% |
| BioAtla, Inc. | -129.68 Million USD | 1013.661% |
| NLS Pharmaceutics AG | -11.8 Million USD | 10135.519% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 7579.013% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 461.54% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 2937.54% |
| XOMA Corporation | -41.84 Million USD | 2931.438% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 1225.935% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 1075.266% |
| aTyr Pharma, Inc. | -54.91 Million USD | 2257.541% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 1455.302% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 785.428% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 565.671% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 5619.892% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 14527.558% |
| Akari Therapeutics, Plc | -16.8 Million USD | 7150.458% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 13399353.423% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -251.005% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 18234.313% |
| UroGen Pharma Ltd. | -65.53 Million USD | 1908.014% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 1427.203% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 16414.168% |
| Orgenesis Inc. | -53.63 Million USD | 2309.151% |
| Entera Bio Ltd. | -8.89 Million USD | 13426.96% |
| GH Research PLC | -41.22 Million USD | 2974.436% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 4709.071% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 1526.679% |
| Xencor, Inc. | -138.63 Million USD | 954.666% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 23087.311% |
| Replimune Group, Inc. | -234.77 Million USD | 604.7% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 5613.44% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 8592.689% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 18234.313% |
| Portage Biotech Inc. | -18.25 Million USD | 6591.536% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 16460.465% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 1228.895% |
| OncoCyte Corporation | -25.13 Million USD | 4813.956% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 10581.336% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 10442.094% |
| Purple Biotech Ltd. | 22.27 Million USD | -5220.372% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 15873.429% |
| scPharmaceuticals Inc. | -55.39 Million USD | 2238.963% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 6370.078% |
| HilleVax, Inc. | -133.34 Million USD | 988.597% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 9934.011% |
| Tharimmune, Inc. | -9.45 Million USD | 12631.702% |
| Genprex, Inc. | -31.07 Million USD | 3912.963% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 729.616% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 3876.333% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 154988.889% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 21853.582% |
| OKYO Pharma Limited | -15.74 Thousand USD | 7523403.574% |
| Savara Inc. | -60 Million USD | 2074.603% |
| Curis, Inc. | -48.33 Million USD | 2551.585% |
| Daré Bioscience, Inc. | -30.83 Million USD | 3942.103% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 22811.068% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 16382.809% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 4448.257% |
| BeiGene, Ltd. | -1.2 Billion USD | 198.109% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 6042.536% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 343.214% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 1365.216% |
| Erasca, Inc. | -141.52 Million USD | 937.237% |
| bluebird bio, Inc. | -244.26 Million USD | 585.094% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 26274.217% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -509.388% |
| DBV Technologies S.A. | -76.43 Million USD | 1650.267% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 26274.217% |
| Moderna, Inc. | -4.23 Billion USD | 127.952% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 2880.868% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 18730.503% |
| Molecular Templates, Inc. | -10.46 Million USD | 11421.422% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 1862.274% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 414.511% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 926.803% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 2378.961% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 866.717% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 669.308% |
| MacroGenics, Inc. | -168.24 Million USD | 804.275% |
| RenovoRx, Inc. | -11.39 Million USD | 10497.508% |
| Adicet Bio, Inc. | -152.03 Million USD | 879.345% |
| Prime Medicine, Inc. | -191.29 Million USD | 719.42% |
| Aditxt, Inc. | -26.06 Million USD | 4646.392% |
| Adagene Inc. | -23.71 Million USD | 5095.391% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 16309.085% |
| Quantum-Si incorporated | -111.17 Million USD | 1165.836% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 3843.996% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 8228.13% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -871.118% |
| SciSparc Ltd. | -5.77 Million USD | 20624.857% |
| Vericel Corporation | -6.46 Million USD | 18430.755% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 13787.721% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 5225.094% |
| Generation Bio Co. | -138.56 Million USD | 955.134% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 1527.075% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 1470.46% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 591.454% |
| Invivyd, Inc. | -207.78 Million USD | 670.258% |
| Relay Therapeutics, Inc. | -373 Million USD | 417.668% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 12734.211% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -5416.037% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 11618.421% |
| 2seventy bio, Inc. | -216.7 Million USD | 646.785% |
| ADMA Biologics, Inc. | 21.63 Million USD | -5377.533% |
| Clene Inc. | -40.54 Million USD | 3022.792% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 5021.119% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 2262.384% |
| GeoVax Labs, Inc. | -26.74 Million USD | 4530.702% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 438.485% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 3325.796% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -7270.156% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 1242.601% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 3584.795% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 795.862% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 273.154% |
| Evaxion Biotech A/S | -22.19 Million USD | 5438.109% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 1538.3% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 631.05% |
| Trevena, Inc. | -35.28 Million USD | 3457.799% |
| Surrozen, Inc. | -45.78 Million USD | 2688.248% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 1582.144% |
| Cingulate Inc. | -22.75 Million USD | 5306.249% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -15715.537% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 2752.741% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 14490.436% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 1255.346% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 1714.767% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 2008.851% |
| Clearmind Medicine Inc. | -8.74 Million USD | 13655.114% |
| Kronos Bio, Inc. | -121.83 Million USD | 1072.585% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 1655.069% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 40499.116% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 1275.181% |
| Statera Biopharma, Inc. | -98.34 Million USD | 1304.855% |
| ImmunityBio, Inc. | -362.25 Million USD | 427.095% |
| Korro Bio, Inc. | -84.53 Million USD | 1501.685% |
| Kineta, Inc. | -15.72 Million USD | 7636.094% |
| BioVie Inc. | -32.17 Million USD | 3782.148% |
| Codexis, Inc. | -68.06 Million USD | 1840.734% |
| Celularity Inc. | -192.28 Million USD | 716.214% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 632.281% |
| Celcuity Inc. | -66.23 Million USD | 1889.059% |
| Virax Biolabs Group Limited | -6.49 Million USD | 18339.128% |
| Cibus, Inc. | -318.88 Million USD | 471.578% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 2855.581% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 3601.064% |
| IN8bio, Inc. | -30.33 Million USD | 4005.792% |
| Kodiak Sciences Inc. | -277.32 Million USD | 527.267% |
| Annexon, Inc. | -143.72 Million USD | 924.433% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 1057.178% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 1932.905% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 5154.172% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 434.973% |
| Eyenovia, Inc. | -25.4 Million USD | 4763.777% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -3530.208% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 21403.488% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 1597.353% |
| Arcellx, Inc. | -89.88 Million USD | 1418.313% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 2709.222% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 963.586% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 3908.866% |
| Moolec Science SA | -6.65 Million USD | 17907.856% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 2038.075% |
| Geron Corporation | -193.94 Million USD | 710.95% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 2839.463% |
| Royalty Pharma plc | 1.49 Billion USD | 20.591% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 821.787% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 12802.798% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 5511.821% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 793.098% |
| Humacyte, Inc. | -100.04 Million USD | 1284.343% |
| Structure Therapeutics Inc. | -102.77 Million USD | 1252.907% |
| 89bio, Inc. | -151.2 Million USD | 883.643% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 1578.685% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 8249.243% |
| Genelux Corporation | -24.16 Million USD | 5003.373% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 3592.91% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 789.898% |
| Notable Labs, Ltd. | -14.65 Million USD | 8184.192% |
| Liquidia Corporation | -73.38 Million USD | 1714.657% |
| Mustang Bio, Inc. | -50.72 Million USD | 2435.883% |
| Immunovant, Inc. | -282.7 Million USD | 519.124% |
| Quantum-Si incorporated | -111.17 Million USD | 1165.836% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 1617.099% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 5671.543% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 1261.53% |
| Acasti Pharma Inc. | -11.31 Million USD | 10574.717% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 5269.472% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 7515.19% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 653.552% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 32394.27% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 7558.769% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 4163.861% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 2963.184% |
| PepGen Inc. | -84.76 Million USD | 1497.848% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 4098.853% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 5274.914% |
| Solid Biosciences Inc. | -104.31 Million USD | 1235.886% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 3711.606% |
| Immuneering Corporation | -58.41 Million USD | 2128.491% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 23377.899% |
| Silo Pharma, Inc. | -3.85 Million USD | 30831.986% |
| Belite Bio, Inc | -31.66 Million USD | 3841.632% |
| XOMA Corporation | -41.84 Million USD | 2931.438% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 1854.887% |
| Bionomics Limited | -17.89 Billion USD | 106.622% |
| Apogee Therapeutics, Inc. | -93 Million USD | 1374.045% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -3220.908% |
| uniQure N.V. | -282.87 Million USD | 518.884% |
| Cassava Sciences, Inc. | -105.95 Million USD | 1218.284% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 16309.085% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 1014.952% |
| Forte Biosciences, Inc. | -32.48 Million USD | 3747.417% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 14360.861% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 4130.958% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 21403.488% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 8438.494% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 13429.958% |
| Altimmune, Inc. | -95.92 Million USD | 1335.184% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 1712.24% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -3220.908% |
| Compugen Ltd. | -12.99 Million USD | 9220.228% |
| Peak Bio, Inc. | -1356.23 USD | 87367286.982% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 2488.719% |
| Benitec Biopharma Inc. | -22.49 Million USD | 5368.564% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 589.016% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 4083.393% |
| Zura Bio Limited | -62.63 Million USD | 1991.663% |
| PolyPid Ltd. | -22.86 Million USD | 5281.703% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 7380.044% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 4083.393% |
| Instil Bio, Inc. | -159.16 Million USD | 844.429% |
| argenx SE | -425.04 Million USD | 378.768% |
| Immunome, Inc. | -109.53 Million USD | 1181.804% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 2452.719% |
| Verona Pharma plc | -67.83 Million USD | 1846.844% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 4646.815% |
| Shattuck Labs, Inc. | -91.95 Million USD | 1388.537% |
| CervoMed Inc. | -7.81 Million USD | 15265.953% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 1720.709% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 8994.978% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 2559.626% |
| Moolec Science SA | -6.65 Million USD | 17907.856% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 7303.723% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 976.233% |
| AnaptysBio, Inc. | -164.41 Million USD | 820.694% |
| Design Therapeutics, Inc. | -78.19 Million USD | 1615.411% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 1461.312% |
| NeurAxis, Inc. | -6.66 Million USD | 17879.292% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 3025.751% |
| Lumos Pharma, Inc. | -36.61 Million USD | 3336.194% |
| Achilles Therapeutics plc | -75.25 Million USD | 1674.513% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 4646.815% |
| 180 Life Sciences Corp. | -13.47 Million USD | 8891.69% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -22879.607% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 40499.116% |
| Nutriband Inc. | -4.87 Million USD | 24420.977% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 1169.597% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 2236.919% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 2430.829% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 1892.614% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 2289.269% |
| Palisade Bio, Inc. | -13.07 Million USD | 9165.8% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 2709.395% |
| Beam Therapeutics Inc. | -176.48 Million USD | 771.389% |
| Neurogene Inc. | -55.58 Million USD | 2231.767% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 1185.531% |
| AEON Biopharma, Inc. | -48.42 Million USD | 2546.675% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 1325.209% |
| Sesen Bio, Inc. | -25.9 Million USD | 4673.314% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 1518.549% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 9513.759% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 357.274% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 1735.721% |
| Athira Pharma, Inc. | -125.46 Million USD | 1044.399% |
| Vaccinex, Inc. | -22.88 Million USD | 5277.627% |
| HCW Biologics Inc. | -25.71 Million USD | 4707.429% |
| XOMA Corporation | -41.84 Million USD | 2931.438% |
| Nektar Therapeutics | -137.42 Million USD | 962.216% |
| Arvinas, Inc. | -401.5 Million USD | 395.118% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 13399353.423% |
| Merus N.V. | -156.54 Million USD | 856.897% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 1281.815% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 3522.588% |
| Rezolute, Inc. | -70.42 Million USD | 1782.547% |
| Clene Inc. | -40.54 Million USD | 3022.792% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 7334.496% |
| BeyondSpring Inc. | -23.11 Million USD | 5226.33% |
| Synlogic, Inc. | -55.16 Million USD | 2248.076% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 6708.846% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 11046.97% |
| Peak Bio, Inc. | -1356.23 USD | 87367286.982% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 3025.462% |
| Krystal Biotech, Inc. | -109.72 Million USD | 1179.862% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 1014.698% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 445.439% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 25066.535% |
| MannKind Corporation | 8.67 Million USD | -13554.068% |
| Ikena Oncology, Inc. | -75.41 Million USD | 1671.131% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 12382.575% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 1862.457% |
| Gossamer Bio, Inc. | -183.75 Million USD | 744.812% |
| CohBar, Inc. | -12.38 Million USD | 9664.672% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 2435.975% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 4395.139% |
| Legend Biotech Corporation | -439.48 Million USD | 369.611% |
| Mural Oncology plc | -194.63 Million USD | 708.771% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 1864.741% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 7438.992% |
| Disc Medicine, Inc. | -91.12 Million USD | 1400.302% |
| Champions Oncology, Inc. | -7.35 Million USD | 16207.939% |
| REGENXBIO Inc. | -268.12 Million USD | 541.916% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 11155.041% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 2225.152% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 3141.274% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 1136.141% |
| Vaxart, Inc. | -83.34 Million USD | 1521.647% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 14007.264% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 2868.841% |
| Cellectis S.A. | -106.62 Million USD | 1211.267% |
| Longeveron Inc. | -21.02 Million USD | 5734.6% |
| Repare Therapeutics Inc. | -116.22 Million USD | 1119.497% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 542.417% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 1666.396% |
| Revolution Medicines, Inc. | -487.18 Million USD | 343.214% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 17912.688% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 2795.773% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 1688.551% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 1801.587% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 10861.057% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 72.492% |
| Denali Therapeutics Inc. | -196.69 Million USD | 702.392% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 13787.721% |
| Veru Inc. | -93.78 Million USD | 1363.459% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 5179.086% |
| Cingulate Inc. | -22.75 Million USD | 5306.249% |
| Passage Bio, Inc. | -108.38 Million USD | 1193.192% |
| Context Therapeutics Inc. | -25.07 Million USD | 4825.873% |
| Exicure, Inc. | -14.99 Million USD | 8001.44% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 675.016% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 3018.617% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 12294.172% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 742.72% |
| Nuvalent, Inc. | -149.49 Million USD | 892.618% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 14520.966% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 1435.384% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 5803.764% |
| OmniAb, Inc. | -69.41 Million USD | 1806.881% |
| Anew Medical, Inc. | -1.3 Million USD | 91187.297% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 9378.052% |
| Lipocine Inc. | -17.93 Million USD | 6708.125% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 1829.453% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 1655.967% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 3211.99% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 3097.698% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 5393.513% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 304.346% |
| Ocugen, Inc. | -65.53 Million USD | 1908.152% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 1362.331% |
| Q32 Bio Inc. | -92.1 Million USD | 1386.508% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 5626.844% |
| Alumis Inc. Common Stock | -158.17 Million USD | 849.112% |
| Equillium, Inc. | -14.52 Million USD | 8259.344% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 1998.696% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 15092.379% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 6380.908% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 2623.695% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 1192.416% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 9998.902% |
| Dominari Holdings Inc. | -21.79 Million USD | 5536.319% |
| Edesa Biotech, Inc. | -9.22 Million USD | 12947.567% |
| vTv Therapeutics Inc. | -25.5 Million USD | 4746.302% |
| Bio-Techne Corporation | 206.68 Million USD | -473.285% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 402.666% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | -517.039% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 995.772% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 3186.4% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 884.177% |
| Nkarta, Inc. | -131.65 Million USD | 1000.038% |
| BioCardia, Inc. | -11.64 Million USD | 10276.056% |
| Iterum Therapeutics plc | -47.46 Million USD | 2596.208% |